Evidence map›Paper›PMID 40333935›Full record

ArticleAnnals of clinical and translational neurology2025

Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis-Frontotemporal Spectrum Disorder.

Greet Vanderlinden, Charles Carron, Donatienne Van Weehaeghe, Joke De Vocht, Fouke Ombelet, Pegah Masrori, Caro De Weerdt, Rebecca E James, Lauren T Evans, Frederick A Schroeder and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. First-in-human PET study of [Journal of translational medicine · 2026
    Article
  2. Charcot-Marie-Tooth disease and related neuropathies.Nature reviews. Disease primers · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Greet VanderlindenNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.ORCID 0000-0002-5673-4121
Charles CarronNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Donatienne Van WeehaegheNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Joke De VochtDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Fouke OmbeletDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Pegah MasroriDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Caro De WeerdtNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Rebecca E JamesEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Lauren T EvansEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Frederick A SchroederEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Jacob M HookerEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Michel KooleNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
Janice E KranzEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Tonya M GilbertEikonizo Therapeutics, Inc., Cambridge, Massachusetts, USA.
Philip Van DammeDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-4010-2357
Koen Van LaereNuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.

Funding

Association for Frontotemporal DegenerationEikonizo TherapeuticsTarget ALS
6 · The paper itself

Abstract

objective[

methodsTwenty-four pwALS (13M/11F, 61 ± 10 years) and 12 healthy controls (HC) (6M/6F, 58 ± 3 years) were included. Thirteen pwALS were cognitively normal (ALS-CN), and eleven pwALS presented with FTSD (ALS-FTSD) ranging from mild cognitive or behavioral impairment to FTD, according to their performance on the Edinburgh cognitive and behavioral ALS screen (ECAS). All subjects underwent dynamic PET-MR imaging with arterial sampling, and regional distribution volumes (V

results[

interpretation[

Indexed as

Amyotrophic Lateral SclerosisBrainCognitive DysfunctionFrontotemporal DementiaHistone Deacetylase 6Positron-Emission TomographyAgedFemaleHumansMaleMiddle AgedHDAC6 protein, humanHistone Deacetylase 6amyotrophic lateral sclerosishistone deacetylase 6positron emission tomography

Identifiers

PMID40333935
PMCPMC12257136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.